Dev Priya Arya
Principal investigator.
Biotech
Built from public records only: federal awards, patents, filings and papers.Is this you? Contact Noair Lab to claim this profile, correct it or hide it.
2015First federal award
$10.7MFederal grants as PI25 awards
0Patents grantedNone matched
0PapersOpenAlex
Federal awards and patents by year
AwardsPatents
25 awards · $10.7M
| Date | Agency | Award | Amount | Company |
|---|---|---|---|---|
| Jan 24, 2024 | NIH | STTR Phase II Aminoglycosides with reduced ototoxicity | $1000K | NUBAD LLC |
| Jan 9, 2024 | NIH | STTR Phase II Development of peptide nucleic acid antibiotics-supplement 1 | $133K | NUBAD LLC |
| Jan 4, 2024 | NIH | STTR Phase II Development of peptide nucleic acid antibiotics | $999K | NUBAD LLC |
| Nov 22, 2023 | NIH | STTR Phase II Development of peptide nucleic acid antibiotics | $33K | NUBAD LLC |
| Feb 15, 2023 | NIH | STTR Phase II Aminoglycosides with reduced ototoxicity | $1000K | NUBAD LLC |
| Jan 9, 2023 | NIH | STTR Phase II Development of peptide nucleic acid antibiotics | $1000K | NUBAD LLC |
| Mar 24, 2021 | NIH | STTR Phase II Aminoglycosides with reduced ototoxicity | $1000K | NUBAD LLC |
| Feb 11, 2021 | NIH | STTR Phase I Delivery of chemically modified PNA oligomers | $474K | NUBAD LLC |
| Feb 8, 2021 | NIH | STTR Phase II Development of peptide nucleic acid antibiotics | $1000K | NUBAD LLC |
| Feb 5, 2021 | NIH | STTR Phase I Supplement Request Alain Letou | $17K | NUBAD LLC |
| Feb 4, 2021 | NIH | STTR Phase I Supplement Request LIDIA.AZANKIA | $13K | NUBAD LLC |
| Mar 6, 2020 | NIH | STTR Phase I Delivery of chemically modified PNA oligomers | $300K | NUBAD LLC |
| Feb 13, 2020 | NIH | STTR Phase I Aminoglycosides with reduced ototoxicity via miRNA targeting | $398K | NUBAD LLC |
| Aug 9, 2019 | NIH | STTR Phase I Aminoglycosides with reduced ototoxicity via miRNA targeting | $45K | NUBAD LLC |
| Jul 10, 2019 | NIH | STTR Phase I Aminoglycosides with reduced ototoxicity via miRNA targeting | $12K | NUBAD LLC |
| Mar 12, 2019 | NIH | STTR Phase I Aminoglycosides with reduced ototoxicity via miRNA targeting | $300K | NUBAD LLC |
| Nov 13, 2018 | NIH | STTR Phase I Nucleobase aminosugars with reduced ototoxicity | $364K | NUBAD LLC |
| Nov 27, 2017 | NIH | STTR Phase I Nucleobase aminosugars with reduced ototoxicity | $306K | NUBAD LLC |
| Jul 26, 2017 | NIH | STTR Phase I Aminoglycosides with reduced ototoxicity | $300K | NUBAD LLC |
| Jun 19, 2017 | NIH | STTR Phase I Screening the Ribosome for New Target Sites | $325K | NUBAD LLC |
| Jul 25, 2016 | NIH | STTR Phase I Aminoglycosides with reduced ototoxicity | $300K | NUBAD LLC |
| Jul 13, 2016 | NIH | STTR Phase I Screening the Ribosome for New Target Sites | $325K | NUBAD LLC |
| Sep 21, 2015 | NIH | STTR Phase II A Rapid assay for RNA targeted drugs: Instrumentation Supplement | $82K | NUBAD LLC |
| Jun 18, 2015 | NIH | STTR Phase II A Rapid Assay for RNA Targeted Drugs | $664K | NUBAD LLC |
| Apr 24, 2015 | NIH | STTR Phase I Development of Peptide Antibiotic Nucleic Acids | $300K | NUBAD LLC |
Peer ranks
Federal funding#56
Awards as PI#10
Patents#273
Companies
- NUBAD LLCLinked by awards · Biotech
Federal awards through Oct 21, 2026 and patents through Oct 20, 2026. Awards come from NIH, NSF and other agency records that name a principal investigator; DoD and NASA contract awards do not, so they are not shown here. Researchers are matched by name and company.